Pelthos Therapeutics Inc.
PTHS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $7 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $3 | $0 | $0 | $0 |
| Gross Profit | $4 | $0 | $0 | $0 |
| % Margin | 54.3% | – | – | – |
| R&D Expenses | $0 | $1 | $0 | $0 |
| G&A Expenses | $0 | $3 | $2 | $2 |
| SG&A Expenses | $19 | $3 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $19 | $3 | $2 | $2 |
| Operating Income | -$15 | -$3 | -$2 | -$2 |
| % Margin | -207.4% | – | – | – |
| Other Income/Exp. Net | -$1 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$17 | -$3 | -$2 | -$2 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$16 | -$3 | -$2 | -$2 |
| % Margin | -219.3% | – | – | – |
| EPS | -25.35 | -5.38 | -3.2 | -3.23 |
| % Growth | -371.2% | -68.1% | 0.9% | – |
| EPS Diluted | -25.35 | -5.38 | -3.2 | -3.23 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $0 | $0 | $0 |
| EBITDA | -$14 | -$3 | -$2 | -$2 |
| % Margin | -191.9% | – | – | – |